basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroids
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Kidney Transplantation
Conditions
Kidney Transplantation
Trial Timeline
May 1, 2005 → Mar 1, 2009
NCT ID
NCT00113269About basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroids
basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroids is a approved stage product being developed by Astellas Pharma for Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT00113269. Target conditions include Kidney Transplantation.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplantation were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00113269 | Approved | Completed |
Competing Products
20 competing products in Kidney Transplantation